Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 338

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 338
---
 unrelated vendor payables of $579,989.

#### Cash Flows from Investing Activities
For the nine months ended September 30, 2024, there was cash provided by investing activities of $2,025,592, which was the result of proceeds from the Trust Account used for tax redemptions and payments in the amount of $1,802,869 and $354,519, which was offset by the advances to the Trust Account of $131,796.

For the nine months ended September 30, 2023, there was cash provided by investing activities of $11,432,625, which was the result of cash proceeds from the Trust Account for tax payments and redemption adjustments of $11,510,446, offset by advances to the Trust Account of $77,821.

For the year ended December 31, 2023, cash provided by investing activities was $11,389,930, which was the result of proceeds from the Trust Account used for redemptions in the amount of $10,657,185, and proceeds from the Trust account used for tax payments of $853,261, net of advances from the trust of $120,516.

For the year ended December 31, 2022, net cash provided by investing activities was $263,963,913, which was the result of proceeds from the Trust Account for redemptions in the amount of $279,091,534, net of advances from the Trust Account of $15,127,621.

#### Cash Flows from Financing Activities
For the nine months ended September 30, 2024, net cash provided by financing activities was $497,131, which was a result of the proceeds from the Liminatus promissory note of $2,300,000, offset by the redemption of Iris Class A Common Stock of $1,802,869.

<div align='center'>181</div>

TABLE OF CONTENTS

For the nine months ended September 30, 2023, net cash used in financing activities was $9,913,465, which was a result of Iris Class A Common Stock that was redeemed in December 2022 and September 2023 for $10,657,185, which was offset by proceeds from the promissory note from a related party for $393,720 and the proceeds from the promissory note from Liminatus for $350,000.

For the year ended December 31, 2023, net cash used in financing activities was